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Background:  Endothelial function has an independent predictive value in patients with cardiovascular disease. Impaired renal function 
is a major determinant of adverse prognosis in heart failure (HF). We examined the impact of atorvastatin treatment and renal function on 
endothelial function and biomarkers of inflammation in HF patients.
methods:  We studied the effect of 4 weeks administration of atorvastatin in 23 patients with ischemic HF. The study was carried out on two 
separate arms, one with atorvastatin 40mg/d and one with atorvastatin 10mg/d (randomized, double-blind, cross-over design). Endothelial 
function was evaluated by flow-mediated dilation (FMD) of the brachial artery. Tumor necrosis factor alpha (TNFa), brain natriuretic peptide 
(BNP) and matrix metalloproteinase-9 (MMP9) levels were measured by ELISA as biomarkers of inflammatory status, left ventricle loading 
and cardiac remodeling respectively. Total cholesterol (TC) levels were also measured.
results:  Compared to baseline, treatment with 40 mg/d of atorvastatin improved FMD (3.16±2.98% vs. 6.05±2.45%, p=0.001), TNFa 
(p=0.01) and MMP9 levels (p=0.04) while there was no impact in BNP levels (p=0.66). Moreover, compared to baseline, treatment with 
atorvastatin 10mg/d also improved FMD (3.24±3.12% vs. 4.20±2.09%, p=0.08) and TNFa (p=0.01) but had no impact on MPP9 (p=0.76) 
and BNP (p=0.40). The increase in FMD was greater with the dose of 40mg/d (p=0.001). In the 40mg/d treatment group the increase in 
FMD was significantly associated with baseline TC levels (r=0.57, p=0.004) and with creatinine clearance (r=0.61, p=0.002). In the 40mg/d 
treatment group the association between creatinine clearance and FMD was also significant even after adjustment for confounders such as 
TC, age, ejection fraction smoking habits, the presence of diabetes mellitus and hypertension [b=0.09, 95%CI: 0.02-0.16, p=0.01].
conclusion:  In ischemic HF subjects atorvastatin treatment improved inflammatory status and endothelial function. Importantly, the 
greatest improvement in endothelial function was observed in patients receiving high dose atorvastatin treatment with elevated baseline TC 
levels and preserved renal function.
